In a stock purchase transaction, the outstanding stock of the target company is transferred directly by its stockholders to the purchaser, with a stock purchase agreement serving as the primary governing...
Recreational cannabis continues to gain in popularity as more states legalize its use. To meet this growing demand, an increasing number of landlords are renting space to cannabis retail businesses. Both...
This practice note explains whether and how drug, medical device, biologics, and other life sciences companies should include ADR mechanisms in their contracts to resolve commercial disputes. Read now...
Do you need to understand when a U.S. employer may have to comply with U.S. labor and employment laws extraterritorially and when a foreign employer with operations in the United States is responsible...
Read this new practice note by Daniel Swanson and Julian Kleinbrodt from Gibson, Dunn & Crutcher to get up to speed on antitrust risks in intellectual property licensing. Leverage legal strategies...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
Despite the various impacts of the COVID-19 pandemic, the life sciences industry has remained among the most active sectors for M&A activity. Check out this practice note, by Reb Wheeler of Mayer Brown LLP, focusing on issues common in life sciences M&A transactions and discussing some of the factors contributing to robust deal activity in the industry in recent years and what may be in store as industry participants continue to navigate a world transformed by COVID-19.
READ NOW »
Related Content
Practical Guidance Updates Featuring the latest updates from your Practical Guidance account.
Experience results today with practical guidance, legal research, and data-driven insights—all in one place.Experience Lexis+